JPRN-UMIN000005414已完成2 期
A Multicenter Phase II Study of Tri-weekly Nab-Paclitaxel for Patients with Metastatic Breast Cancer Pretreated with Taxanes (SBCCSG-20) - Phase II Study of Tri-weekly Nab-Paclitaxel for MBC Pretreated with Taxanes (SBCCSG-20)
Saitama Breast Cancer Clinical Study Group(SBCCSG)0 个研究点目标入组 35 人开始时间: 2011年4月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Either of ER, PgR, HER2 is positive by surgical specimen. 2) Previously treated with Nab-paclitaxel. 3) Confirmed histologically HER2 positive. 4) History of serious allergy for paclitaxel or albumin 5) Serious complication. (intestinal paralysis, intestinal obstruction, interstitial pneumonia, lung fibrosis, uncontrolled diabetes mellitus) 6) Symptomatic brain metastasis 7) Active other malignancies 8) Severe psychiatric disorders 9) During pregnancy 10) Patients judged inappropriate by physicians
研究者
相似试验
招募中
2 期
Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer.JPRN-UMIN000010579Department of gastroenterologic and breast surgery Kanazawa University,School of Medicine35
进行中（未招募）
2 期
Biweekly chemotherapy with nab-Paclitaxel plus Gemcitabine for elderly patinents of unresectable pancreatic cancerPancreatic cancerJPRN-jRCTs051190038Ikezawa Kenji20
招募中
2 期
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancerbreast cancerJPRN-UMIN000041509Breast Surgery, Yokkaichi Municipal Hospital20
已完成
2 期
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancerbreast cancerJPRN-UMIN000032153Yokkaichi Municipal Hospital50
进行中（未招募）
1 期
Study to evaluate the impact of VCN-01 on the overall survival of patients with advanced pancreatic cancer treated with standard therapy.Metastatic Pancreatic CancerMedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2022-000897-24-DETheriva Biologics, S.L.92